Literature DB >> 33069697

Prolonged use of nitric oxide donor sodium nitroprusside induces ocular hypertension in mice.

Chunchun Hu1, Yu Zhang2, Maomao Song1, Yonghui Deng2, Xinghuai Sun3, Yuan Lei4.   

Abstract

Nitric oxide (NO) donors are promising therapeutic candidates for treating intraocular hypertension (IOP) and glaucoma. This study aims to investigate the effect of prolonged use of NO donor sodium nitroprusside (SNP) on IOP. Since SNP has a short biological half-life, a nanoparticle drug delivery system (mesoporous silica nanoparticles) has been used to deliver SNP to the target tissues (trabecular meshwork and Schlemm's canal). We find that the sustained use of NO donor initially reduced IOP followed, surprisingly, by IOP elevation, which could not recover by drug withdraw but could be reversed by the antioxidant MnTMPyP application. The IOP elevation and normalization coincide with increased and reduced protein nitration in the mouse conventional outflow tissue. These findings suggest that the prolonged use of NO donor SNP may be problematic as it can cause outflow tissue damage by protein nitration. MnTMPyP is protective of the nitrative damage which could be considered to be co-applied with NO donors.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Antioxidant; Intraocular hypertension; Mesoporous silica nanoparticles; Nitric oxide donor; Peroxynitrite anion

Mesh:

Substances:

Year:  2020        PMID: 33069697     DOI: 10.1016/j.exer.2020.108280

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  2 in total

1.  Efficacy and safety of Shenfu injection combined with sodium nitroprusside in the treatment of chronic heart failure in patients with coronary heart disease: A protocol of randomized controlled trial.

Authors:  Binbin Guo; Tian Yang; Jinniang Nan; Qianghui Huang; Chenxiu Wang; Wenpeng Xu
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

Review 2.  The Application of Nitric Oxide for Ocular Hypertension Treatment.

Authors:  Binze Han; Maomao Song; Liping Li; Xinghuai Sun; Yuan Lei
Journal:  Molecules       Date:  2021-12-01       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.